Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Since my August article on Edgewise Therapeutics (NASDAQ: EWTX ), the stock nearly doubled at one point after producing strong midstage data from a program in which it has an ongoing late stage study. This program is targeting BeckerAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.  ...